SELExipag in inoperable or persistent/recurrent Chronic Thromboembolic pulmonary hypertension. A multicenter, randomized, double-blind, placebo-controlled, parallel-group, group-sequential, adaptive, Phase 3 study with open-label extension period to assess the efficacy and safety of selexipag as an add-on to standard of care therapy in subjects with inoperable or persistent/recurrent after surgical and /or interventional treatment Chronic Thromboembolic Pulmonary Hypertension.